RT Journal Article
SR Electronic
T1 Development and Validation of a Multivariable Risk Prediction Model for Sudden Cardiac Death after Myocardial Infarction (PROFID Risk Model): Study Rationale, Design and Protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.12.21260002
DO 10.1101/2021.07.12.21260002
A1 Martin, Glen P.
A1 Hindricks, Gerhard
A1 Akbarov, Artur
A1 Kapacee, Zoher
A1 Parkes, Le Mai
A1 Motamedi-Ghahfarokhi, Golnoosh
A1 Ng, Stephanie
A1 Sprague, Daniel
A1 Taleb, Youssef
A1 Ong, Marcus
A1 Longato, Enrico
A1 Miller, Christopher A.
A1 Shamloo, Alireza Sepehri
A1 Albert, Christine
A1 Barthel, Petra
A1 Boveda, Serge
A1 Braunschweig, Frieder
A1 Johansen, Jens Brock
A1 Cook, Nancy
A1 de Chillou, Christian
A1 Elders, Petra J.M.
A1 Faxen, Jonas
A1 Friede, Tim
A1 Fusini, Laura
A1 Gale, Chris P.
A1 Jarkovsky, Jiri
A1 Jouven, Xavier
A1 Junttila, Juhani
A1 Kiviniemi, Antti
A1 Kutyifa, Valentina
A1 Lee, Daniel
A1 Leigh, Jill
A1 Lenarczyk, Radosław
A1 Leyva, Francisco
A1 Maeng, Michael
A1 Manca, Andrea
A1 Marijon, Eloi
A1 Marschall, Ursula
A1 Vinayagamoorthy, Manickavasagar
A1 Nielsen, Jens Cosedis
A1 Olsen, Thomas
A1 Pester, Julie
A1 Pontone, Gianluca
A1 Schmidt, Georg
A1 Schwartz, Peter J.
A1 Sticherling, Christian
A1 Suleiman, Mahmoud
A1 Taborsky, Milos
A1 Tan, Hanno L.
A1 Tflt-Hansen, Jacob
A1 Tijssen, Jan G.P.
A1 Tomaselli, Gordon
A1 Verstraelen, Tom
A1 Warnakula Olesen, Kevin Kris
A1 Wilde, Arthur A.M.
A1 Willems, Rik
A1 Willems, Dick L.
A1 Wu, Katherine
A1 Zabel, Markus
A1 Peek, Niels
A1 Dagres, Nikolaos
YR 2021
UL http://medrxiv.org/content/early/2021/07/16/2021.07.12.21260002.abstract
AB Introduction Sudden cardiac death (SCD) is the leading cause of death in patients with myocardial infarction (MI) and can be prevented by the implantable cardioverter defibrillator (ICD). Currently, risk stratification for SCD and decision on ICD implantation are based solely on impaired left ventricular ejection fraction (LVEF). However, this strategy leads to over- and under-treatment of patients because LVEF alone is insufficient for accurate assessment of prognosis. Thus, there is a need for better risk stratification. This is the study protocol for developing and validating a prediction model for risk of SCD in patients with prior MI.Methods and Analysis The EU funded PROFID project will analyse 23 datasets from Europe, Israel and the US (∼225,000 observations). The datasets include patients with prior MI or ischemic cardiomyopathy with reduced LVEF<50%, with and without a primary prevention ICD. Our primary outcome is SCD in patients without an ICD, or appropriate ICD therapy in patients carrying an ICD as a SCD surrogate. For analysis, we will stack 18 of the datasets into a single database (datastack), with the remaining analysed remotely for data governance reasons (remote data). We will apply 5 analytical approaches to develop the risk prediction model in the datastack and the remote datasets, all under a competing risk framework: 1) Weibull model, 2) flexible parametric survival model, 3) random forest, 4) likelihood boosting machine, and 5) neural network. These dataset-specific models will be combined into a single model (one per analysis method) using model aggregation methods, which will be externally validated using systematic leave-one-dataset-out cross-validation. Predictive performance will be pooled using random effects meta-analysis to select the model with best performance.Ethics and dissemination Local ethical approval was obtained. The final model will be disseminated through scientific publications and a web-calculator. Statistical code will be published through open-source repositories.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/A - protocol paperFunding StatementThe work described is part of the PROFID project. This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 847999Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Whenever required by national or local regulations all individual participating databases were approved by their respective ethical boards (see below details where this was required). Data Controller approvals were obtained for all other datasets that did not require ethical approval. All data was shared under data sharing agreements, and was handled strictly in adherence to GDPR, European laws and local data safety protocols. Centro Cardiologico Monzino Registry, local IRB details: - Comitato Etico, Centro CARDIOLOGICO Monzino c/o Istituto Europeo di Oncologia Via Ripamonti, 435 20141 MILANO. - Decision: Approved Helios Hospital EHR, local IRB details: - Universitat Leipzig, Medizinische Fakultat, Ethik-Kommission, Kathe-Kollwitz-Str. 82, 04109 Leipzig, Germany - Decision: Ethical approval was given. No objections to the retrospective data analysis as long as the data are anonymised (which they will be). PRE-DETERMINE, local IRB details: - Mass General Brigham IRB, Mass General Brigham, 399 Revolution Drive, Suite 710, Somerville, MA 02145, Tel: 857-282-1900, Fax: 857-282-5693 - IRB Protocol Number: 2007P000840 - Decision: This project has been reviewed and approved by the MGB IRB. During the review of this project, the IRB specifically considered (i) the risks and anticipated benefits, if any, to subjects; (ii) the selection of subjects; (iii) the procedures for obtaining and documenting informed consent; (iv) the safety of subjects; and (v) the privacy of subjects and confidentiality of the data Swedish Registry, local IRB details: - Swedish Ethical Review Authority - Decision: Approved (Dnr 2020-04158) All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will not be able to share the individual participant data owing to the required data sharing agreements and considerations